Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
779
mi
from
Lansing, MI
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
779
mi
from
Lansing, MI
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
1035
mi
from
Missoula, MT
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1035
mi
from
Missoula, MT
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
1287
mi
from
Brooklyn, NY
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1287
mi
from
Brooklyn, NY
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
1043
mi
from
Chapel Hill, NC
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1043
mi
from
Chapel Hill, NC
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
732
mi
from
Cincinnati, OH
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
732
mi
from
Cincinnati, OH
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
192
mi
from
Muskogee, OK
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
192
mi
from
Muskogee, OK
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
New York Methodist Hospital
1287
mi
from
Brooklyn, NY
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
New York Methodist Hospital
1287
mi
from
Brooklyn, NY
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
722
mi
from
Chattanooga, TN
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
722
mi
from
Chattanooga, TN
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
348
mi
from
Fort Worth, TX
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
348
mi
from
Fort Worth, TX
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Clinical Research Facility
1410
mi
from
Seattle, WA
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1410
mi
from
Seattle, WA
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Status: Archived
Clinical Trial Facility
1320
mi
from
Santa Clara, CA
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1320
mi
from
Santa Clara, CA
Multi-Center Study of Iron Overload: Pilot and Survey Study
Pilot Study Examining Mechanisms of Iron Trafficking and Extra-hepatic Iron Distribution in Sickle Cell Disease, Thalassemia, and Other Iron Loading Anemias
Status: Archived
Children's Hospital Los Angeles ( Gastroenterology & Nutrition)
1168
mi
from
Los Angeles, CA
Multi-Center Study of Iron Overload: Pilot and Survey Study
Pilot Study Examining Mechanisms of Iron Trafficking and Extra-hepatic Iron Distribution in Sickle Cell Disease, Thalassemia, and Other Iron Loading Anemias
Status: Archived
Updated: 1/1/1970
Children's Hospital Los Angeles ( Gastroenterology & Nutrition)
1168
mi
from
Los Angeles, CA
Multi-Center Study of Iron Overload: Pilot and Survey Study
Pilot Study Examining Mechanisms of Iron Trafficking and Extra-hepatic Iron Distribution in Sickle Cell Disease, Thalassemia, and Other Iron Loading Anemias
Status: Archived
Children's Hospital Central California
1215
mi
from
Madera, CA
Multi-Center Study of Iron Overload: Pilot and Survey Study
Pilot Study Examining Mechanisms of Iron Trafficking and Extra-hepatic Iron Distribution in Sickle Cell Disease, Thalassemia, and Other Iron Loading Anemias
Status: Archived
Updated: 1/1/1970
Children's Hospital Central California
1215
mi
from
Madera, CA
Multi-Center Study of Iron Overload: Pilot and Survey Study
Pilot Study Examining Mechanisms of Iron Trafficking and Extra-hepatic Iron Distribution in Sickle Cell Disease, Thalassemia, and Other Iron Loading Anemias
Status: Archived
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Multi-Center Study of Iron Overload: Pilot and Survey Study
Pilot Study Examining Mechanisms of Iron Trafficking and Extra-hepatic Iron Distribution in Sickle Cell Disease, Thalassemia, and Other Iron Loading Anemias
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Novo Nordisk Clinical Trial Call Center
856
mi
from
Peoria, AZ
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
856
mi
from
Peoria, AZ
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Novo Nordisk Clinical Trial Call Center
1171
mi
from
Long Beach, CA
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
1171
mi
from
Long Beach, CA
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Rhode Island Hospital
1424
mi
from
Providence, RI
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
Rhode Island Hospital
1424
mi
from
Providence, RI
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Darien Pediatric Associates
1314
mi
from
Darien, CT
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
1314
mi
from
Darien, CT
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
UVM Health Behavior Research Center
1357
mi
from
South Burlington, VT
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
UVM Health Behavior Research Center
1357
mi
from
South Burlington, VT
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Novo Nordisk Clinical Trial Call Center
1445
mi
from
North Dartmouth, MA
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
1445
mi
from
North Dartmouth, MA
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Novo Nordisk Clinical Trial Call Center
841
mi
from
Detroit, MI
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
841
mi
from
Detroit, MI
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Novo Nordisk Clinical Trial Call Center
196
mi
from
Kansas City, MO
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
196
mi
from
Kansas City, MO
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Coastal Connecticut Research, LLC
1387
mi
from
New London, CT
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
Coastal Connecticut Research, LLC
1387
mi
from
New London, CT
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Novo Nordisk Clinical Trial Call Center
1288
mi
from
New York, NY
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
1288
mi
from
New York, NY
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
St. Luke Whiteside Research
689
mi
from
Duluth, MN
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
St. Luke Whiteside Research
689
mi
from
Duluth, MN
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Novo Nordisk Clinical Trial Call Center
1384
mi
from
Portland, OR
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
1384
mi
from
Portland, OR
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Novo Nordisk Clinical Trial Call Center
1063
mi
from
Charleston, SC
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
1063
mi
from
Charleston, SC
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Novo Nordisk Clinical Trial Call Center
348
mi
from
Fort Worth, TX
Safety and Efficacy of Recombinant Factor VIII (N8) in Previously Treated Male Children With Haemophilia A
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
348
mi
from
Fort Worth, TX
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Dana-Farber / Harvard Cancer Center
1444
mi
from
Boston, MA
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Dana-Farber / Harvard Cancer Center
1444
mi
from
Boston, MA
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Clinical Research Facility
1320
mi
from
Miami, FL
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1320
mi
from
Miami, FL
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Clinical Research Facility
540
mi
from
Alexandria, LA
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
540
mi
from
Alexandria, LA
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Clinical Research Facility
348
mi
from
Fort Worth, TX
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
348
mi
from
Fort Worth, TX
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Phase 2 Study of Canfosfamide HCl for Injection (Telcyta®, TLK286)in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM)
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
1263
mi
from
New Brunswick, NJ
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Phase 2 Study of Canfosfamide HCl for Injection (Telcyta®, TLK286)in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM)
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
1263
mi
from
New Brunswick, NJ
A Study in Benign Prostatic Hyperplasia
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Archived
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
1489
mi
from
Scarborough, ME
A Study in Benign Prostatic Hyperplasia
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
1489
mi
from
Scarborough, ME
A Study in Benign Prostatic Hyperplasia
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Archived
Clinical Research Facility
1287
mi
from
Brooklyn, NY
A Study in Benign Prostatic Hyperplasia
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1287
mi
from
Brooklyn, NY
A Study in Benign Prostatic Hyperplasia
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Archived
New York Methodist Hospital
1287
mi
from
Brooklyn, NY
A Study in Benign Prostatic Hyperplasia
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
New York Methodist Hospital
1287
mi
from
Brooklyn, NY
Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine
Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine
Status: Archived
Washington Hospital Center
1127
mi
from
Washington,
Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine
Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine
Status: Archived
Updated: 1/1/1970
Washington Hospital Center
1127
mi
from
Washington,
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Comprehensive Blood and Cancer Center
1188
mi
from
Bakersfield, CA
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Comprehensive Blood and Cancer Center
1188
mi
from
Bakersfield, CA
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Hematology Oncology Associates of Northern NJ
1262
mi
from
Morristown, NJ
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of Northern NJ
1262
mi
from
Morristown, NJ
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Loma Linda Medical Center
1114
mi
from
Loma Linda, CA
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Loma Linda Medical Center
1114
mi
from
Loma Linda, CA
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Santa Barbara Hematology Oncology
1242
mi
from
Santa Barbara, CA
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Santa Barbara Hematology Oncology
1242
mi
from
Santa Barbara, CA
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
James R. Berenson, MD, Inc
1175
mi
from
West Hollywood, CA
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
James R. Berenson, MD, Inc
1175
mi
from
West Hollywood, CA
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Watson Clinic Center for Research, Inc.
1135
mi
from
Lakeland, FL
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Watson Clinic Center for Research, Inc.
1135
mi
from
Lakeland, FL
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Bassett Healthcare
1251
mi
from
Cooperstown, NY
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Bassett Healthcare
1251
mi
from
Cooperstown, NY
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Broome Oncology
1194
mi
from
Binghamton, NY
A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Broome Oncology
1194
mi
from
Binghamton, NY
Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body Compression Fractures
A Pilot Study of Vertebral Augmentation With Kyphoplasty Versus Nonsurgical Management in Multiple Myeloma Patients With Mildly Symptomatic Vertebral Body Compression Fractures
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
1112
mi
from
Tampa, FL
Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body Compression Fractures
A Pilot Study of Vertebral Augmentation With Kyphoplasty Versus Nonsurgical Management in Multiple Myeloma Patients With Mildly Symptomatic Vertebral Body Compression Fractures
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
1112
mi
from
Tampa, FL
Telomere and Telomerase
Telomere and Telomerase
Status: Archived
University of Kansas Medical Center
190
mi
from
Kansas City, KA
Telomere and Telomerase
Telomere and Telomerase
Status: Archived
Updated: 1/1/1970
University of Kansas Medical Center
190
mi
from
Kansas City, KA
Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
The TOPAZ Study: A Long-Term Extension Study in Elderly Subjects With Relapsed/Refractory Acute Myeloid Leukemia to Allow Continued Therapy With Tosedostat
Status: Archived
University of Michigan Health Systems
807
mi
from
Ann Arbor, MI
Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
The TOPAZ Study: A Long-Term Extension Study in Elderly Subjects With Relapsed/Refractory Acute Myeloid Leukemia to Allow Continued Therapy With Tosedostat
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
807
mi
from
Ann Arbor, MI
Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
The TOPAZ Study: A Long-Term Extension Study in Elderly Subjects With Relapsed/Refractory Acute Myeloid Leukemia to Allow Continued Therapy With Tosedostat
Status: Archived
University of Texas M.D. Anderson Cancer Center
572
mi
from
Houston, TX
Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
The TOPAZ Study: A Long-Term Extension Study in Elderly Subjects With Relapsed/Refractory Acute Myeloid Leukemia to Allow Continued Therapy With Tosedostat
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
572
mi
from
Houston, TX
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
ALONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia A
Status: Archived
Clinical Research Facility
1143
mi
from
San Diego, CA
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
ALONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1143
mi
from
San Diego, CA